Working... Menu

Topical Ruxolitinib for the Treatment of Vitiligo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02809976
Recruitment Status : Completed
First Posted : June 22, 2016
Last Update Posted : August 2, 2017
Information provided by (Responsible Party):
Tufts Medical Center

Brief Summary:
The purpose of this study is to determine if topical ruxolitinib 1.5% will provide repigmentation in vitiligo lesions.

Condition or disease Intervention/treatment Phase
Vitiligo Drug: Ruxolitinib 1.5% Phosphate Cream Phase 2

Detailed Description:
The hypothesis is that JAK inhibitors can also successfully treat vitiligo. Lesional skin of both alopecia areata and vitiligo primarily contain T cells in a TH1 response as opposed to a mixed cell infiltrate such as in psoriasis or lichen planus. Both alopecia areata and vitiligo are TH1 mediated diseases dependent on the production of IFN-gamma to drive the response. CD8+ T cells are both necessary and sufficient for melanocyte destruction in vitiligo (van den Boorn JG et al 2009) and CD8+NKG2D+ T cells are also necessary and sufficient for hair loss in alopecia areata (Gilhar A et al 2013).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo
Actual Study Start Date : January 2016
Actual Primary Completion Date : January 2017
Actual Study Completion Date : February 2017

Arm Intervention/treatment
Experimental: Ruxolitinib 1.5% phosphate cream
Ruxolitinib 1.5% phosphate cream twice daily to vitiligo patches.
Drug: Ruxolitinib 1.5% Phosphate Cream
twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
Other Name: INCB018424 phosphate cream

Primary Outcome Measures :
  1. Determine mean and standard deviation percent change in Vitiligo Area Severity Index (VASI) score from Baseline to Week 20 [ Time Frame: 20 weeks ]

Secondary Outcome Measures :
  1. Percent change in body surface area (BSA) of repigmentation [ Time Frame: 20 weeks ]
  2. Proportion of subjects who achieve a Physician Global Vitiligo Assessment (PGVA) of clear or almost clear [ Time Frame: 20 weeks ]
  3. Percent change in Vitiligo European Task Force (VETF) scale [ Time Frame: 20 weeks ]
  4. Percent change in Dermatology Life Quality Index (DLQI) [ Time Frame: 20 weeks ]
  5. Photographic Improvement [ Time Frame: 20 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of vitiligo.
  • At Visit 1 (Baseline/Day 1), have had vitiligo covering at least 1% of total body surface area (BSA) on the scalp, trunk or limbs (excluding nails).
  • Female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least four weeks after the last dose of assigned treatment. Male subjects must also use contraception, such as barrier method with spermicide.
  • If receiving concomitant medications for any reason, must be on a stable regimen and willing to stay on a stable regimen.
  • Must be willing to washout of other vitiligo treatments. All treatments for vitiligo are prohibited during the course of the study.

Exclusion Criteria:

  • Other skin conditions at Baseline that would interfere with evaluation of vitiligo.
  • Pregnant/breastfeeding females, or females of childbearing potential not using highly effective contraception. Women of childbearing potential must test negative for pregnancy and use contraception for at least four weeks after last dose of drug.
  • Current or recent history of clinically significant medical/psychiatric condition or laboratory abnormality that may increase risk associated with the study participation or drug administration.
  • Have a history of any lymphoproliferative disorder, lymphoma, leukemia, history of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
  • Have a history of infection requiring parenteral or oral or topical antimicrobial therapy within 2 weeks prior to Baseline.
  • Vaccinated with live/attenuated live vaccine within 6 weeks prior to Baseline.
  • Previously participated in study of oral/topical ruxolitinib or tofacitinib (tofacitinib, CP-690,550, formerly tasocitinib) unless confirmed to have been randomized to and treated with placebo or placebo topical formulation (vehicle) only.
  • Received a prohibited concomitant medication within 7 days or 5 half-lives (whichever is longer) prior to Baseline.
  • Have participated in other studies within 4 weeks or 5 half-lives (whichever is longer) prior to Visit 1 (Baseline/Day 1). Subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study.
  • Subjects who are investigational site staff members or relatives of those site staff members or subjects who are Sponsor employees directly involved in the conduct of the trial.
  • In the opinion of the investigator or Sponsor, the subject is inappropriate for entry into this study, or unwilling/unable to comply with study procedures and lifestyle guidelines.
  • Screening laboratory abnormalities
  • CYP Inhibitor Exclusion: Subjects taking potent CYP3A4 inhibitors or fluconazole within 2 weeks or 5 half-lives, whichever is longer, before the baseline visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02809976

Layout table for location information
United States, Massachusetts
Tufts Medical Center
Boston, Massachusetts, United States, 02111
Sponsors and Collaborators
Tufts Medical Center
Layout table for investigator information
Principal Investigator: David Rosmarin, MD Tufts Medical Center

Layout table for additonal information
Responsible Party: Tufts Medical Center Identifier: NCT02809976     History of Changes
Other Study ID Numbers: I-18424-15-06
First Posted: June 22, 2016    Key Record Dates
Last Update Posted: August 2, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Pigmentation Disorders
Skin Diseases